Navigation Links
WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
Date:6/10/2008

SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has signed a new three-year collaboration agreement with AstraZeneca.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

In April 2006, WuXi PharmaTech and AstraZeneca entered into a two-year US$14 million collaboration agreement that WuXi PharmaTech successfully delivered more than 100,000 compounds two months ahead of schedule.

"This new collaboration agreement further strengthens our already productive relationship with AstraZeneca, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, "We are hopeful that with our strong and growing drug R&D capabilities the expansion of our collaboration will help AstraZeneca achieve its strategic goals."

Under the new collaboration agreement WuXi PharmaTech will synthesize compounds, according to AstraZeneca's designs, which will further expand AstraZeneca's global compound collection.

"The collaboration with WuXi PharmaTech has exceeded our expectations delivering value to AstraZeneca beyond the cost savings in labor and materials," said Deborah Hartman, Vice President, Lead Generation Discovery Enabling Capabilities and Sciences (DECS), AstraZeneca, "We are looking forward to the prospect of building on this success through our expanded relationship."

High Throughput Screening remains a major source of chemical starting points, making it important to generate many high quality compounds with the proper purity and targeted characteristics. WuXi PharmaTech has developed an innovative, scalable and hi
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
2. WuXi PharmaTech Announces First Quarter 2008 Results
3. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
4. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
5. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
6. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
7. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
8. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
9. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
10. WuXi PharmaTech Completes Acquisition of AppTec
11. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... CALGARY and BLENHEIM, Ontario, Nov. 24 /PRNewswir...today it is acquiring the assets of Hyland Seeds, ...io. The addition of Hyland Seeds will further expa... company anticipates the introduction of SmartSta...Tolerant Trait Technology in corn in 2012. The tra...
(Date:11/24/2009)... Health care employment grew by 29...ly one to show consistent growth during the U.S. r... remain in trouble, and health systems are coming ..., instead of just administrators. , ...e employment continued growing in October despite ...
(Date:11/24/2009)..., SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstC...rmaceutical company focused on developing and comm...nced today that Anthony DiTonno, President and Chi...he 21st Annual Piper Jaffray Health Care Conferenc...alace Hotel in New York, New York. ,, Mr. DiTo...
(Date:11/24/2009)... The FBI recently approved the Prome...participating in or generating DNA records for the... Madison, WI USA (PRWEB) -- The FBI recently a...for use by laboratories participating in, or gener...em (NDIS). NDIS currently contains more than seven...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2
...me Therapeutics, Inc.,(Nasdaq: HALO ), a biopharm...roducts targeting the extracellular matrix for the...ology markets, today reported financial,results fo...08., "The fundamentals for Halozyme have never be...f our Phase 2 insulin clinical trial. The,study wi...
...re-FirstCall/ - Dr. Brad Thompson, President,and C...NCY), will present a,corporate overview of the Com...e Conference on Tuesday, November 11, 2008 at 11:1...Palace Hotel from November 10-12, 2008., A live a... at:, http://www.wsw.com/webcast/rrshq14/oncy or ...
...ate Highlights:, * Submitted NDA with FDA for NGX... with PHN, * Responded to EM...er review for NGX-4010 in peripheral neu...sX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical com...el pain management therapies, today reported resul...
Other Biology Technology:Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 8Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX Reports Third Quarter 2008 Results 2NeurogesX Reports Third Quarter 2008 Results 3NeurogesX Reports Third Quarter 2008 Results 4NeurogesX Reports Third Quarter 2008 Results 5NeurogesX Reports Third Quarter 2008 Results 6NeurogesX Reports Third Quarter 2008 Results 7NeurogesX Reports Third Quarter 2008 Results 8NeurogesX Reports Third Quarter 2008 Results 9
(Date:11/25/2009)...Scientists at the California Institute of Technolo...e emotion-like behavior in the fruit fly, Drosoph...e relevant to the relationship between the neurotr...vity disorder (ADHD), are described in the Decembe...la brain contains only about 20,000 neurons and h...
(Date:11/25/2009)...teria don,t have easy lives. In addition to mammal...e natural enemies called bacteriophages, viruses t.... , Still, bacteria and another class of microo...me environments such as deep-sea volcanic vents) m...ave a built-in defense system that helps protect t...
(Date:11/25/2009)...sch, Head of the Cell Death Research Laboratory in...has been awarded the prestigious Johnson & Johnson...the cause of brain cell damage in Parkinson,s dise...ntists in support of innovation and excellence in ...ferred earlier this month at an event at the Hyatt...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2New Report Emphasizes Critical Role of Including Early and Preventative Care for Women in Health Care Reform 48963 1New Report Emphasizes Critical Role of Including Early and Preventative Care for Women in Health Care Reform 48963 2Insmed CEO Resigns Due to Health Concerns 12633 1Insmed CEO Resigns Due to Health Concerns 12633 2Insmed CEO Resigns Due to Health Concerns 12633 3Colonoscopy Risks Increase With Age and Illness 48960 1Colonoscopy Risks Increase With Age and Illness 48960 2Colonoscopy Risks Increase With Age and Illness 48960 3
...EAGAN, Minn., March 11 Lockheed Martin has receiv...de performance-based logistics support for the AN/...t provides Q-70 logistics and supply support at ov...h options for additional support over the next fou...ue to $72 million. , , This contract follows a re...
... (SAN DIEGO) Central line-associated bloodstream ...uring the past three years at the Hospital of the ...approach combining leadership initiatives, electro...ne insertion and maintenance, and implementation o...ractices in line care. The findings, which Penn ph...
... LAS VEGASExplosive population growth in southern... water resources. In 2007, 80% of the state,s resi...on approached two million people. The dual concern...res frequent severe drought conditions has created...ernative water resources to meet resident and visi...
Other Biology News:U.S. Navy Awards Lockheed Martin Six-year Contract Worth Up to $72 Million for Advanced Display Systems Support 2Penn medicine draws road map for elimination of central line-associated bloodstream infections 2Penn medicine draws road map for elimination of central line-associated bloodstream infections 3Keeping golf courses green when fresh water is limited 2Keeping golf courses green when fresh water is limited 3
Mouse Anti-RYK Monoclonal Antibody, Unconjugated, Clone F30 P7 D7 F5 from Abcam
Pancreatic Cell Cryopreservation Medium from CHEMICON
Mouse Anti-S100 alpha Monoclonal Antibody, Unconjugated, Clone SH-A1 from Abcam
FCS File Sanitizer from Verity Software House
Biology Products: